Drug Trial Radar · NCT05692492
A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Actual
Start
Jun 3, 2023
Primary completion
Jun 16, 2026
Study completion Dec 16, 2026
Sponsor
- Lead sponsor
- Guangdong Raynovent Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research is to evaluate the efficacy and the safety of two doses of ZSP1601 for 48 weeks versus placebo in adult NASH patients.
Conditions
- Nonalcoholic Steatohepatitis (NASH)
Interventions
ZSP1601Drug
50mg BID
ZSP1601Drug
100mg BID
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of patients with improvement of steatohepatitis and no worsening of liver fibrosis or improvement in liver fibrosis greater than or equal to one stage and no worsening of the steatohepatitisTime frame: 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NanFang Hospital
Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.